- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07723833
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
This is a phase I, open-label, randomized, 2-period crossover study with 4-cohorts. All 4 cohorts are independent and non-sequential parts in this study. Each cohort will evaluate 2 formulations (test formulation and reference formulation) of elecoglipron across 2 study treatment periods. Participants within each cohort will be randomized to one of 2 treatment sequences (Test-Reference or Reference-Test).
In total 3 formulations will be evaluated at 2 dose levels each:
- Reference formulation
- Test formulation 1
- Test formulation 2
The study will comprise:
- A Screening Period.
- 2 treatment periods in each cohort - Period 1, and Period 2 during which participants will be admitted to the Clinical Unit and receive a single oral dose of elecoglipron in each period.
- A final Follow-up Visit.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 1. fázis
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: AstraZeneca Clinical Study Information Center
- Telefonszám: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Tanulmányi helyek
-
-
California
-
Glendale, California, Egyesült Államok, 91206
- Toborzás
- Research Site
-
-
Maryland
-
Brooklyn, Maryland, Egyesült Államok, 21225
- Toborzás
- Research Site
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- Healthy participants with suitable veins for cannulation or repeated venipuncture.
- All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
- Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception.
- Females of non-childbearing potential must be confirmed at screening visit as postmenopausal or have documentation of irreversible surgical sterilization.
- Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods.
- Have a body mass index between 18.5 and 30 kg/m2 inclusive and weigh at least 50 kg.
Exclusion Criteria:
- History of any clinically important disease or disorder.
- History of acute pancreatitis.
- History or presence of gastrointestinal (GI) or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.
- Any clinically important illness, medical/surgical procedure, or trauma.
- Participants who have previously received elecoglipron within the last 3 months.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Crossover kiosztás
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Cohort 1-Treatment Sequence A
Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose A) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
Kísérleti: Cohort 1 - Treatment Sequence B
Participant will receive a single dose of elecoglipron test formulation 1 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
Kísérleti: Cohort 2 - Treatment Sequence C
Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose B) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
Kísérleti: Cohort 2 - Treatment Sequence D
Participant will receive a single dose of elecoglipron test formulation 1 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
Kísérleti: Cohort 3 - Treatment Sequence E
Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose A) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
Kísérleti: Cohort 3 - Treatment Sequence F
Participant will receive a single dose of elecoglipron test formulation 2 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
Kísérleti: Cohort 4 - Treatment Sequence G
Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose B) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
Kísérleti: Cohort 4 - Treatment Sequence H
Participant will receive a single dose of elecoglipron test formulation 2 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Maximum observed drug concentration (Cmax)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Time to reach maximum observed concentration (tmax)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Terminal elimination rate constant (λz)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Terminal elimination half-life (t1/2λz)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Apparent total body clearance (CL/F)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUCinf (R AUCinf)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUClast (R AUClast)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on Cmax (R Cmax)
Időkeret: At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Number of participants with adverse events (AEs)
Időkeret: From screening (Day -28) up to follow-up visit (Day 18-Day 22)
|
To assess the safety and tolerability of different formulations of elecoglipron following single oral administration in healthy participants.
|
From screening (Day -28) up to follow-up visit (Day 18-Day 22)
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- D7260C00023
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD megosztási időkeret
IPD-megosztási hozzáférési feltételek
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .